Dialysis-Related Amyloidosis Treatment Act of 2024
This bill adds specific Medicare coverage for treatments targeting dialysis-related amyloidosis (DRA), a condition affecting some long-term dialysis patients. It directly affects Medicare beneficiaries diagnosed with DRA and dialysis facilities providing these treatments. The bill defines DRA treatments as FDA-approved items/services in dialysis settings and mandates separate 100% payment for them - outside standard dialysis fees - ensuring coverage without being bundled into existing payment systems. This change takes effect upon the bill's enactment.
Bill status
in committee
1 of 4 stages cleared
Introduction
Jul 2024
Committee Review
Floor Vote
President
Introduced Jul 11, 2024
Last action Dec 17, 2024
Floor votes
How they voted
No floor votes recorded yet.
Full legislative history
Actions timeline
Total actions
3
Key actions
0
Committee
2
Dec 17, 2024
Committee
Referred to the Subcommittee on Health.
lower
Jul 11, 2024
Committee
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
lower
Jul 11, 2024
Introduced
Introduced in House
lower
1 primary · 2 co-sponsors
Sponsors
Role
Legislator
Party
State
District
P
Brian Babin
RRepublican
Co
David G. Valadao
RRepublican
Co
Jerrold Nadler
DDemocratic
Ask Maddy
·
AI policy assistant
Ask Maddy about HR 8999
Scope: US
Hi! I can help you understand HR 8999. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline